tiprankstipranks
Trending News
More News >
Theravance Biopharma (TBPH)
NASDAQ:TBPH
US Market
Advertisement

Theravance Biopharma (TBPH) Earnings Dates, Call Summary & Reports

Compare
324 Followers

Earnings Data

Report Date
Mar 02, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
1
Last Year’s EPS
-0.31
Same Quarter Last Year
Based on 5 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 10, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial position with record sales and profitability for YUPELRI, significant progress in ampreloxetine's clinical trials, and upcoming milestone achievements for Trelegy. Despite minor operational challenges, the overall outlook remains positive with a focus on future growth and strategic objectives.
Company Guidance
During the Theravance Biopharma Third Quarter 2025 Conference Call, the company reported robust financial performance and progress in its strategic objectives. The third quarter saw YUPELRI achieving record net sales of $71.4 million, a 15% year-over-year increase, driven by a 6% increase in demand and improved net pricing. This positions YUPELRI to trigger a $25 million milestone from Viatris with just $54 million in sales needed in Q4. Theravance also highlighted the advancement of the pivotal Phase III Cyprus trial of ampreloxetine, targeting a data readout in early 2026, which could significantly impact the company’s valuation. The company ended the quarter with $333 million in cash and no debt, anticipating $75 million in near-term milestones. Furthermore, the strong performance of Trelegy, with $1 billion in sales for the quarter, is expected to yield a $50 million milestone in Q4 and $100 million in 2026. The company maintains a focus on financial discipline, achieving non-GAAP breakeven, and aims to leverage its robust balance sheet and strategic initiatives for long-term value creation.
YUPELRI Sales Growth
Third quarter net sales for YUPELRI increased 15% year over year to $71.4 million, driven by a 6% increase in demand and favorable net pricing.
Record Profitability and Financial Strength
Theravance achieved non-GAAP breakeven and ended the quarter with $333 million in cash and no debt. The company is on track to achieve near-term milestones totaling $75 million in the fourth quarter.
Trelegy Milestone Achievements
Trelegy sales reached $1 billion for the quarter, setting up the achievement of a $50 million milestone in 2025 and a $100 million milestone in 2026.
Ampreloxetine Phase III Progress
The pivotal Phase III Cyprus trial for ampreloxetine is on track for data readout in early 2026, with significant progress in NDA preparation. A KOL event for investors is planned to highlight its potential.

Theravance Biopharma (TBPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

TBPH Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 02, 2026
2025 (Q4)
0.99 / -
-0.31
Nov 10, 2025
2025 (Q3)
-0.13 / 0.07
-0.26126.92% (+0.33)
Aug 12, 2025
2025 (Q2)
0.67 / 1.08
-0.34417.65% (+1.42)
May 08, 2025
2025 (Q1)
-0.21 / -0.27
-0.24-12.50% (-0.03)
Feb 26, 2025
2024 (Q4)
-0.20 / -0.31
-0.17-82.35% (-0.14)
Nov 12, 2024
2024 (Q3)
-0.23 / -0.26
-0.17-52.94% (-0.09)
Aug 05, 2024
2024 (Q2)
-0.21 / -0.34
-0.28-21.43% (-0.06)
May 13, 2024
2024 (Q1)
-0.25 / -0.24
-0.3531.43% (+0.11)
Feb 26, 2024
2023 (Q4)
-0.15 / -0.17
-0.15-13.33% (-0.02)
Nov 07, 2023
2023 (Q3)
-0.21 / -0.17
12.14-101.40% (-12.31)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

TBPH Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 10, 2025
$15.08$18.50+22.68%
Aug 12, 2025
$11.92$12.42+4.19%
May 08, 2025
$9.90$8.98-9.29%
Feb 26, 2025
$9.08$9.27+2.09%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Theravance Biopharma (TBPH) report earnings?
Theravance Biopharma (TBPH) is schdueled to report earning on Mar 02, 2026, Before Open (Confirmed).
    What is Theravance Biopharma (TBPH) earnings time?
    Theravance Biopharma (TBPH) earnings time is at Mar 02, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is TBPH EPS forecast?
          TBPH EPS forecast for the fiscal quarter 2025 (Q4) is 1.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis